Person: YILDIZ, PELİN
Now showing 1 - 2 of 2
- PublicationOpen AccessImmunoexpression of TTF-1 in Non-Lung Tumors(2014-12-01T00:00:00Z) TOSUNER, ZEYNEP; ARICI, Dilek Sema; GÜCİN, ZÜHAL; BÜYÜKPINARBAŞILI, NUR; SÖNMEZ, FATMA CAVİDE; YILDIZ, PELİN; TOSUNER, ZEYNEP; ARICI, DILEK SEMA; GÜCİN, ZÜHAL; BÜYÜKPINARBAŞILI, NUR; SÖNMEZ, FATMA CAVİDE; YILDIZ, PELİNObjective: Thyroid transcription factor-1 (TTF-1) immunoexpression is frequently determined in small-cell lung carcinomas, as well as primary lung adenocarcinomas. While dealing with metastatic carcinomas, TTF-1 immunoexpression is a significant indicator of primary lung carcinomas. Recent studies have revealed that TTF-1 immunoexpression is also defined in non-lung cancers, such as squamous cell carcinomas of different sites and certain neuroendocrine tumors. The verified data obtained from these studies indicate that a straightforward diagnosis of primary lung carcinoma in cases with positive TTF-1 immunoexpression can cause diagnostic contradictions. The aim of our study is to investigate the immunoexpression status of TTF-1 in common non-lung tumors. Methods: A total of 85 cases that were diagnosed in our institute between the years 2011-2012 were included in our study. After a review of the pathological slides prepared from these tumors [colon adenocarcinoma (n: 15), renal cell carcinoma (n: 15), prostate adenocarcinoma (n: 15), invasive papillary urothelial carcinoma (n: 15), invasive ductal carcinoma of breast (n: 15), and neuroendocrine tumors (n: 10)] TTF-1 immunohistochemistry was applied. Semiquantative evaluation based on the distribution and intensity of the staining was performed by two pathologists, respectively. Results: Positive immunostaining was evident in only 1 case of colon adenocarcinoma out of 85 cases. Conclusion: Our study demonstrated that TTF-1 immunoexpression is a very rare finding (1%) in non-lung tumors. This result provides that anti-TTF-1 is a reliable antibody in the interpretation of primary lung carcinomas. In fact, further studies with a large number of cases are needed to confirm the sensitivity and specificity of TTF-1.
- PublicationOpen AccessExpression of transient receptor potential melastatin 4 in differential diagnosis of eosinophilic renal tumors(2021-11-01T00:00:00Z) ÇOBAN, GANİME; YILDIZ, PELİN; DOĞAN, BAYRAM; ŞAHİN, NURHAN; GÜCİN, ZÜHAL; ÇOBAN, GANİME; YILDIZ, PELİN; DOĞAN, BAYRAM; ŞAHİN, NURHAN; GÜCİN, ZÜHALImmunohistochemical and molecular studies to differentiate eosinophilic kidney tumors are gradually increasing. The present study investigated the role of transient receptor potential cation channel subfamily M member 4 (TRPM4), a non-selective cation channel associated with migration, proliferation and invasion in cancer cells, in this differentiation. The aim was to investigate the effectiveness of TRPM4 in differentiation of eosinophilic kidney tumors. The study included a total of 112 patients, including 97 eosinophilic kidney tumors with the diagnoses of 33 eosinophilic clear cell renal cell carcinoma (CCRCC), 35 eosinophilic chromophobe renal cell carcinoma (ChRCC), 8 papillary renal cell carcinoma type 2 (P2RCC), 21 renal oncocytoma (RO), as well as 15 papillary renal cell carcinoma type 1 to differentiate from P2RCC. For TRPM4, diffuse staining (>10%) was observed in 2 CCRCC, 15 ChRCC, 20 RO and 4 P2RCC cases. There was a significant difference between eosinophilic CCRCC and other eosinophilic tumors (P<0.05). While basolateral staining was observed in papillary tumors, membrane staining was observed in other stained cases. It was hypothesized that the use of TRPM4 along with morphological findings, cytokeratin 7 and other markers may be useful for the differentiation of eosinophilic kidney tumors.